Sponsor pipeline

National Cancer Institute (NCI) clinical trial pipeline

Get alerts when National Cancer Institute (NCI)'s trials change

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-20

What changed in the last 30 days

103 trials changed in the last 30 days: 2 stopped, 47 with notable changes, 54 with minor changes only.

Stopped

Drug Selinexor With Radiation Therapy · Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Recruitment suspended

National Cancer Institute (NCI)Phase 1/2 NCT05099003 Registry history of NCT05099003 on ClinicalTrials.gov (opens the registry)

Oct 13, 2026
Stopped

Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Recruitment suspended

National Cancer Institute (NCI)Phase 1 NCT07055477 Registry history of NCT07055477 on ClinicalTrials.gov (opens the registry)

Oct 1, 2026
Notable

Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Primary and study completion pushed from Nov 30, 2029 to Dec 25, 2032

National Cancer Institute (NCI)Phase 3 NCT06589804 Registry history of NCT06589804 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Notable

Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Primary and study completion pushed from Jan 31, 2027 to Jan 31, 2030

National Cancer Institute (NCI)Phase 3 NCT04267848 Registry history of NCT04267848 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Notable

Allogeneic Hematopoietic Stem Cell Transplant · Inborn Errors of Immunity

Primary completion pushed from Oct 1, 2026 to Oct 1, 2028

Also in this update: Study completion pushed from Nov 30, 2027 to Nov 30, 2032

National Cancer Institute (NCI)Phase 2 NCT04339777 Registry history of NCT04339777 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Notable

Immunotherapy (Ipilimumab and Nivolumab) · Recurrent Glioma With Elevated Mutational Burden

Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027

National Cancer Institute (NCI)Phase 2 NCT04145115 Registry history of NCT04145115 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Notable

Lutetium Lu 177 Dotatate · Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Primary and study completion pushed from Jul 1, 2027 to Sep 1, 2032

National Cancer Institute (NCI)Phase 2 NCT04665739 Registry history of NCT04665739 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Notable

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) · Advanced Solid Tumors

Primary and study completion pushed from Sep 30, 2026 to Sep 30, 2028

National Cancer Institute (NCI)Phase 1 NCT03366116 Registry history of NCT03366116 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Notable

Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Primary and study completion pushed from Oct 23, 2026 to Oct 23, 2027

National Cancer Institute (NCI)Phase 2 NCT05859334 Registry history of NCT05859334 on ClinicalTrials.gov (opens the registry)

Oct 15, 2026
Notable

TAK-243 · Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

Primary and study completion pushed from Oct 24, 2026 to Oct 24, 2027

National Cancer Institute (NCI)Phase 1 NCT03816319 Registry history of NCT03816319 on ClinicalTrials.gov (opens the registry)

Oct 16, 2026
Notable

Atezolizumab Alone or Atezolizumab Plus Bevacizumab · Advanced Alveolar Soft Part Sarcoma

Primary and study completion pushed from Oct 31, 2026 to Oct 31, 2027

National Cancer Institute (NCI)Phase 2 NCT03141684 Registry history of NCT03141684 on ClinicalTrials.gov (opens the registry)

Oct 14, 2026
Notable

Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Primary and study completion pushed from Nov 2, 2026 to Jun 1, 2027

National Cancer Institute (NCI)Phase 2 NCT05691465 Registry history of NCT05691465 on ClinicalTrials.gov (opens the registry)

Oct 14, 2026
Notable

Immunotherapy Agents Rituximab or Mosunetuzumab · Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

Primary and study completion pushed from Oct 31, 2026 to Oct 31, 2028

National Cancer Institute (NCI)Phase 2 NCT05886036 Registry history of NCT05886036 on ClinicalTrials.gov (opens the registry)

Oct 14, 2026
Notable

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Primary and study completion pushed from Jan 31, 2027 to Aug 2, 2027

National Cancer Institute (NCI)Phase 1/2 NCT05896839 Registry history of NCT05896839 on ClinicalTrials.gov (opens the registry)

Oct 14, 2026
Notable

How the Body Responds to the Drug CBX-12 · Advanced Solid Cancers

Primary and study completion pushed from Oct 15, 2026 to Oct 15, 2028

National Cancer Institute (NCI)Phase 1 NCT05691517 Registry history of NCT05691517 on ClinicalTrials.gov (opens the registry)

Oct 15, 2026
Notable

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab · Metastatic Genitourinary Tumors

Primary and study completion pushed from Sep 30, 2026 to Jul 30, 2027

National Cancer Institute (NCI)Phase 1 NCT02496208 Registry history of NCT02496208 on ClinicalTrials.gov (opens the registry)

Oct 15, 2026
Notable

Bevacizumab and Anetumab Ravtansine or Paclitaxel · Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary and study completion pushed from Oct 21, 2026 to Dec 15, 2027

National Cancer Institute (NCI)Phase 2 NCT03587311 Registry history of NCT03587311 on ClinicalTrials.gov (opens the registry)

Oct 13, 2026
Notable

Immunotherapy Versus Observation · HPV Throat Cancer

Primary and study completion pushed from Jan 1, 2027 to Jan 31, 2030

National Cancer Institute (NCI)Phase 3 NCT03811015 Registry history of NCT03811015 on ClinicalTrials.gov (opens the registry)

Sep 29, 2026
Notable

Osimertinib With or Without Bevacizumab as Initial Treatment · EGFR-Mutant Lung Cancer

Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2029

National Cancer Institute (NCI)Phase 3 NCT04181060 Registry history of NCT04181060 on ClinicalTrials.gov (opens the registry)

Changed Sep 30, 2026
Notable

Use of Combination Therapy · Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Primary and study completion pushed from Aug 31, 2026 to Dec 31, 2030

National Cancer Institute (NCI)Phase 2 NCT05554419 Registry history of NCT05554419 on ClinicalTrials.gov (opens the registry)

Oct 1, 2026

Show 54 trials with minor changes only

Minor

AMBASSADOR · MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

Primary and study completion pushed from Oct 31, 2026 to Jan 1, 2027

National Cancer Institute (NCI)Phase 3 NCT03244384 Registry history of NCT03244384 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Minor

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib · Advanced Kidney Cancer, The PDIGREE Study

Primary and study completion pushed from Jan 25, 2028 to Mar 1, 2028

National Cancer Institute (NCI)Phase 3 NCT03793166 Registry history of NCT03793166 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Minor

Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Primary and study completion pushed from Apr 1, 2028 to Aug 13, 2028

National Cancer Institute (NCI)Phase 2/3 NCT03984448 Registry history of NCT03984448 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Minor

Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Enrollment closed, study ongoing

National Cancer Institute (NCI)Phase 3 NCT05256225 Registry history of NCT05256225 on ClinicalTrials.gov (opens the registry)

Oct 2, 2026
Minor

Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Primary and study completion pushed from Apr 1, 2027 to Aug 1, 2027

National Cancer Institute (NCI)Phase 1 NCT04609046 Registry history of NCT04609046 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Minor

Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib · Advanced Solid Tumors, The ComBET Trial

Enrollment closed, study ongoing

Also in this update: Study completion moved earlier from Dec 31, 2027 to Dec 31, 2026

National Cancer Institute (NCI)Phase 2 NCT05327010 Registry history of NCT05327010 on ClinicalTrials.gov (opens the registry)

Sep 25, 2026
Minor

Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Trial completed

Also in this update: Primary completion date changed from estimate of Nov 30, 2026 to May 6, 2025

National Cancer Institute (NCI)Phase 1/2 NCT04708470 Registry history of NCT04708470 on ClinicalTrials.gov (opens the registry)

Sep 22, 2026
Minor

Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant

Enrollment closed, study ongoing

Also in this update: Final enrollment: 35 participants (planned 222)

National Cancer Institute (NCI)Not applicable NCT05605574 Registry history of NCT05605574 on ClinicalTrials.gov (opens the registry)

Oct 2, 2026
Minor

ANVIL · Nivolumab After Surgery and Chemotherapy · Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

Primary and study completion pushed from Dec 31, 2026 to May 31, 2027

National Cancer Institute (NCI)Phase 3 NCT02595944 Registry history of NCT02595944 on ClinicalTrials.gov (opens the registry)

Sep 29, 2026
Minor

Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Primary and study completion pushed from Dec 31, 2026 to Mar 31, 2027

National Cancer Institute (NCI)Phase 2 NCT04310007 Registry history of NCT04310007 on ClinicalTrials.gov (opens the registry)

Sep 29, 2026
Minor

Pomalidomide Treatment · Kaposi Sarcoma

Primary and study completion pushed from Oct 1, 2026 to Feb 4, 2027

National Cancer Institute (NCI)Phase 2 NCT04577755 Registry history of NCT04577755 on ClinicalTrials.gov (opens the registry)

Sep 28, 2026
Minor

PRISMA · Single-Dose HPV Vaccination · Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial

Primary completion pushed from Aug 31, 2026 to Sep 30, 2026

National Cancer Institute (NCI)Phase 4 NCT05237947 Registry history of NCT05237947 on ClinicalTrials.gov (opens the registry)

Sep 21, 2026
Minor

Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Trial sites expanded: 100 → 104 locations

And 3 more changes in the last 30 days

National Cancer Institute (NCI)Phase 3 NCT07388524 Registry history of NCT07388524 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Minor

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib · Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Trial sites expanded: 280 → 285 locations

National Cancer Institute (NCI)Phase 2 NCT03739814 Registry history of NCT03739814 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Minor

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone · Aggressive Poorly Differentiated Sarcomas

Trial sites expanded: 261 → 266 locations

And 1 more change in the last 30 days

National Cancer Institute (NCI)Phase 3 NCT06422806 Registry history of NCT06422806 on ClinicalTrials.gov (opens the registry)

Oct 15, 2026
Minor

Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib · High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Trial sites expanded: 203 → 206 locations

And 3 more changes in the last 30 days

National Cancer Institute (NCI)Phase 3 NCT07391774 Registry history of NCT07391774 on ClinicalTrials.gov (opens the registry)

Oct 15, 2026
Minor

Different Treatment Lengths for Venetoclax · Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Trial sites expanded: 37 → 40 locations

And 3 more changes in the last 30 days

National Cancer Institute (NCI)Phase 2 NCT07437950 Registry history of NCT07437950 on ClinicalTrials.gov (opens the registry)

Oct 16, 2026
Minor

Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) · High-risk Multiple Myeloma Refractory or in First Relapse

Trial sites expanded: 21 → 24 locations

And 2 more changes in the last 30 days

National Cancer Institute (NCI)Phase 2 NCT06948084 Registry history of NCT06948084 on ClinicalTrials.gov (opens the registry)

Oct 16, 2026
Minor

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

Enrollment increased: 28 → 40 participants

National Cancer Institute (NCI)Phase 2 NCT05907759 Registry history of NCT05907759 on ClinicalTrials.gov (opens the registry)

Sep 25, 2026
Minor

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Trial sites expanded: 337 → 340 locations

And 1 more change in the last 30 days

National Cancer Institute (NCI)Phase 3 NCT07061977 Registry history of NCT07061977 on ClinicalTrials.gov (opens the registry)

Oct 13, 2026
Minor

Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

Trial sites expanded: 1 → 4 locations

National Cancer Institute (NCI)Phase 2 NCT07516366 Registry history of NCT07516366 on ClinicalTrials.gov (opens the registry)

Oct 15, 2026
Minor

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells · Mesothelin-Expressing Solid Tumors Including Mesothelioma

Enrollment increased: 100 → 120 participants

National Cancer Institute (NCI)Phase 1 NCT06885697 Registry history of NCT06885697 on ClinicalTrials.gov (opens the registry)

Oct 2, 2026
Minor

Teclistamab on Recurrent Plasmablastic Lymphoma

Trial sites expanded: 6 → 14 locations

National Cancer Institute (NCI)Phase 1 NCT07332507 Registry history of NCT07332507 on ClinicalTrials.gov (opens the registry)

Oct 14, 2026
Minor

Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Trial sites expanded: 294 → 302 locations

And 2 more changes in the last 30 days

National Cancer Institute (NCI)Phase 3 NCT07198074 Registry history of NCT07198074 on ClinicalTrials.gov (opens the registry)

Oct 6, 2026
Minor

Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Trial sites expanded: 68 → 71 locations

And 1 more change in the last 30 days

National Cancer Institute (NCI)Phase 2 NCT06917911 Registry history of NCT06917911 on ClinicalTrials.gov (opens the registry)

Oct 6, 2026
Minor

Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery · Sinonasal Squamous Cell Carcinoma

Trial sites expanded: 14 → 18 locations

National Cancer Institute (NCI)Phase 2 NCT07281417 Registry history of NCT07281417 on ClinicalTrials.gov (opens the registry)

Oct 5, 2026
Minor

Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Trial sites expanded: 142 → 145 locations

National Cancer Institute (NCI)Phase 2 NCT06770582 Registry history of NCT06770582 on ClinicalTrials.gov (opens the registry)

Sep 30, 2026
Minor

Combination Targeted Therapy (ViPOR) · Relapsed and/or Refractory Aggressive B-cell Lymphoma

Trial sites expanded: 104 → 113 locations

And 1 more change in the last 30 days

National Cancer Institute (NCI)Phase 2 NCT06649812 Registry history of NCT06649812 on ClinicalTrials.gov (opens the registry)

Sep 29, 2026
Minor

Experimental Approach · Plasma Cell Leukemia, The QUANTUM Trial

Trial sites expanded: 2 → 7 locations

National Cancer Institute (NCI)Phase 2 NCT07605416 Registry history of NCT07605416 on ClinicalTrials.gov (opens the registry)

Sep 24, 2026
Minor

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Trial sites expanded: 165 → 177 locations

National Cancer Institute (NCI)Phase 2 NCT07061964 Registry history of NCT07061964 on ClinicalTrials.gov (opens the registry)

Sep 24, 2026
Minor

Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Final enrollment: 17 participants (planned 66)

Also in this update: Primary completion date changed from estimate of Oct 1, 2026 to Aug 8, 2026; Study completion pushed from Oct 1, 2026 to Oct 15, 2027

National Cancer Institute (NCI)Phase 2 NCT05564403 Registry history of NCT05564403 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Minor

BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Primary completion date changed from estimate of Dec 31, 2026 to Oct 15, 2021

National Cancer Institute (NCI)Phase 2 NCT06400225 Registry history of NCT06400225 on ClinicalTrials.gov (opens the registry)

Oct 15, 2026
Minor

Anti-Cancer Drugs Talazoparib and Temozolomide · Advanced Stage Rare Cancers, RARE 2 Trial

Study completion pushed from Sep 29, 2026 to Sep 23, 2027

National Cancer Institute (NCI)Phase 2 NCT05142241 Registry history of NCT05142241 on ClinicalTrials.gov (opens the registry)

Oct 14, 2026
Minor

Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Primary completion date changed from estimate of Oct 1, 2028 to Sep 23, 2026

Also in this update: Study completion moved earlier from Oct 1, 2028 to Oct 9, 2027

National Cancer Institute (NCI)Phase 2 NCT05554328 Registry history of NCT05554328 on ClinicalTrials.gov (opens the registry)

Oct 13, 2026
Minor

NCI COVID-19 in Cancer Patients, NCCAPS Study

Study completion pushed from Oct 3, 2026 to Oct 14, 2027

National Cancer Institute (NCI)Not specified NCT04387656 Registry history of NCT04387656 on ClinicalTrials.gov (opens the registry)

Oct 16, 2026
Minor

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Study completion pushed from Sep 19, 2026 to Sep 17, 2027

National Cancer Institute (NCI)Phase 1 NCT03816332 Registry history of NCT03816332 on ClinicalTrials.gov (opens the registry)

Oct 14, 2026
Minor

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy · Stage I-III Pleural Malignant Mesothelioma

Study completion pushed from Sep 18, 2026 to Sep 18, 2027

National Cancer Institute (NCI)Phase 1 NCT03228537 Registry history of NCT03228537 on ClinicalTrials.gov (opens the registry)

Oct 14, 2026
Minor

M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy · Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

Study completion pushed from Sep 18, 2026 to Sep 17, 2027

National Cancer Institute (NCI)Phase 1 NCT02589522 Registry history of NCT02589522 on ClinicalTrials.gov (opens the registry)

Oct 14, 2026
Minor

Combination Chemotherapy With or Without Ganitumab · Newly Diagnosed Metastatic Ewing Sarcoma

Study completion pushed from Sep 17, 2026 to Sep 16, 2027

National Cancer Institute (NCI)Phase 3 NCT02306161 Registry history of NCT02306161 on ClinicalTrials.gov (opens the registry)

Oct 6, 2026
Minor

Cabozantinib · Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Study completion pushed from Aug 19, 2026 to Sep 1, 2027

National Cancer Institute (NCI)Phase 3 NCT03375320 Registry history of NCT03375320 on ClinicalTrials.gov (opens the registry)

Sep 22, 2026
Minor

Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy · Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Final enrollment: 68 participants (planned 88)

Also in this update: Primary completion date changed from estimate of Oct 1, 2026 to Jul 16, 2025; Study completion pushed from Oct 1, 2026 to Oct 5, 2027

National Cancer Institute (NCI)Phase 2 NCT04548752 Registry history of NCT04548752 on ClinicalTrials.gov (opens the registry)

Oct 7, 2026
Minor

Pazopanib Hydrochloride · Progressive Carcinoid Tumors

Study completion pushed from Sep 10, 2026 to Sep 10, 2027

National Cancer Institute (NCI)Phase 2 NCT01841736 Registry history of NCT01841736 on ClinicalTrials.gov (opens the registry)

Oct 6, 2026
Minor

MYELOMATCH · Screening Study to Assign · Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Interventions modified

Also in this update: Trial arms changed: 39 → 41; and 1 more change in the last 30 days

National Cancer Institute (NCI)Phase 2 NCT05564390 Registry history of NCT05564390 on ClinicalTrials.gov (opens the registry)

Oct 7, 2026
Minor

Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

Study completion pushed from Oct 31, 2026 to Sep 3, 2027

National Cancer Institute (NCI)Phase 2 NCT04175912 Registry history of NCT04175912 on ClinicalTrials.gov (opens the registry)

Sep 29, 2026
Minor

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery · Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Study completion pushed from Sep 11, 2026 to Sep 30, 2027

National Cancer Institute (NCI)Phase 2 NCT02883062 Registry history of NCT02883062 on ClinicalTrials.gov (opens the registry)

Sep 30, 2026
Minor

Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Final enrollment: 98 participants (planned 134)

Also in this update: Primary completion date changed from estimate of Oct 1, 2026 to Jul 27, 2026; Study completion pushed from Oct 1, 2026 to Sep 24, 2027

National Cancer Institute (NCI)Phase 2 NCT04071223 Registry history of NCT04071223 on ClinicalTrials.gov (opens the registry)

Sep 28, 2026
Minor

Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Final enrollment: 58 participants (planned 70)

Also in this update: Primary completion date changed from estimate of Sep 30, 2026 to Apr 15, 2026; Study completion pushed from Sep 30, 2026 to Sep 23, 2027

National Cancer Institute (NCI)Phase 2 NCT06169215 Registry history of NCT06169215 on ClinicalTrials.gov (opens the registry)

Sep 25, 2026
Minor

XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Study completion pushed from Aug 19, 2026 to Sep 2, 2027

National Cancer Institute (NCI)Phase 2 NCT04079712 Registry history of NCT04079712 on ClinicalTrials.gov (opens the registry)

Sep 22, 2026
Minor

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Interventions modified

National Cancer Institute (NCI)Phase 2 NCT05001880 Registry history of NCT05001880 on ClinicalTrials.gov (opens the registry)

Sep 22, 2026
Minor

Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Study completion pushed from Sep 4, 2026 to Aug 20, 2027

National Cancer Institute (NCI)Phase 2 NCT04729959 Registry history of NCT04729959 on ClinicalTrials.gov (opens the registry)

Sep 23, 2026
Minor

Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma

Primary completion date changed from estimate of Sep 1, 2026 to Jul 30, 2026

Also in this update: Study completion pushed from Dec 1, 2027 to Jun 15, 2028

National Cancer Institute (NCI)Phase 1 NCT02203526 Registry history of NCT02203526 on ClinicalTrials.gov (opens the registry)

Sep 30, 2026
Minor

Trametinib With or Without Whole Brain Radiation Therapy · Brain Metastases

Study completion pushed from Oct 8, 2026 to Sep 23, 2027

National Cancer Institute (NCI)Phase 1 NCT02015117 Registry history of NCT02015117 on ClinicalTrials.gov (opens the registry)

Sep 25, 2026
Minor

Telaglenastat With Radiation Therapy and Temozolomide · IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Final enrollment: 23 participants (planned 40)

Also in this update: Primary completion date changed from estimate of Dec 1, 2026 to Dec 10, 2024; Study completion pushed from Dec 1, 2026 to Sep 18, 2027

National Cancer Institute (NCI)Phase 1 NCT03528642 Registry history of NCT03528642 on ClinicalTrials.gov (opens the registry)

Sep 22, 2026
Minor

Genetic Testing in Screening · Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Final enrollment: 7458 participants (planned 8300)

Also in this update: Primary completion date changed from estimate of Sep 28, 2026 to Dec 3, 2025; Study completion pushed from Sep 28, 2026 to Sep 21, 2027

National Cancer Institute (NCI)Not applicable NCT02194738 Registry history of NCT02194738 on ClinicalTrials.gov (opens the registry)

Sep 23, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

New trial filings, last 30 days

First posted	Trial	Phase	Status
2026-10-07	NCT07862517 Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and…	Phase 2	Not Yet Recruiting

Active trials by phase

Early Phase 1		1
Phase 1		164
Phase 1/2		77
Phase 2		315
Phase 2/3		17
Phase 3		80
Phase 4		3

Not charted: 124 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 50

Leukemia (95) · Lung Cancer (80) · Non-Hodgkin Lymphoma (70) · Sarcoma (67) · Breast Cancer (57) · Multiple Myeloma (52) · Ovarian Cancer (51) · Colorectal Cancer (49) · Head & Neck Cancer (46) · Non-Small Cell Lung Cancer (NSCLC) (46)

Get alerts when National Cancer Institute (NCI)'s trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.

Start monitoring free